Reporter Gene Assay 乐鱼体育官网 Size
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 10.10% |
| Fastest Growing 乐鱼体育官网 | Asia-Pacific |
| Largest 乐鱼体育官网 | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Reporter Gene Assay 乐鱼体育官网 Analysis
The Global Reporter Gene Assay 乐鱼体育官网 is expected to register a CAGR of 10.1% during the forecast period.
Amidst COVID-19, the reporter gene assay 乐鱼体育官网 is expected to grow owing to the rising cases of COVID-19 among people across the globe and the rising demand for vaccines and treatment drugs. The increase in the need for the development of vaccines for COVID-19 infected patients and the diagnosis of people is projected to create lucrative opportunities for the reporter gene assay 乐鱼体育官网. Also, the increasing research on the COVID-19 virus to study the nucleic acid structure to produce suitable vaccine candidates has led to a surge in product approvals and launches. For instance, in August 2021, Creative Diagnostics launched a variety of lentiviral SARS-CoV-2 pseudoviruses from a wide range of coronavirus species. Different vectors can be used to express different reporters such as EGFP or luciferase, allowing the monitoring of viral entry into host cells by a variety of means. Such launches are expected to propel the research and development related to COVID-19 and, thus, COVID-19 is expected to have a significant impact on the growth of the 乐鱼体育官网.
Moreover, the growing preference for cell-based assays is one of the major driving factors for the growth of the reporter gene assay 乐鱼体育官网. This is due to the increasing usage of reported gene assays in life science research and biomanufacturing. The reporter gene assays are a crucial experimental tool to study the biochemistry and physiology of both healthy and diseased cells. Thus, the reporter gene assays gained much attention in studying emerging infectious viruses and developing drug therapies. Additionally, the increasing prevalence of chronic genetic disorders and infectious diseases among the population has led to increased demand for reporter gene assays owing to the cell-based applications in drug discovery. According to a World Health Organization report in 2022, chronic diseases such as cancer are one of the leading causes of death worldwide, accounting for nearly one in six deaths in 2020. The National Human Genome Research Institute report published in January 2020 stated that more than 6,800 rare diseases affect an estimated 25 to 30 million Americans. Therefore, the increasing incidences of rare and genetic disorders coupled with increasing demand for early diagnosis and effective treatment processes are expected to boost the growth of the 乐鱼体育官网.
Additionally, the strategic initiatives undertaken by the 乐鱼体育官网 players are also expected to propel the growth of the 乐鱼体育官网. For instance, in December 2021, Novartis acquired all share capital of the United Kingdom-based ocular gene therapy company Gyroscope therapeutics. This acquisition helped the company, Novartis, extend its portfolio into gene therapy.
Thus, owing to the abovementioned factors, the 乐鱼体育官网 is expected to show growth over the forecast period. However, the high cost of cell-based research may hinder the growth of the 乐鱼体育官网.
Reporter Gene Assay 乐鱼体育官网 Trends
The Assay Kits Segment is Expected to Hold a Major 乐鱼体育官网 Share in the Reporter Gene Assay 乐鱼体育官网
The assay kits segment is expected to register significant revenue over the forecast period. The sudden outbreak of COVID-19 has increased the demand for reporter gene assays owing to their efficiency in studying the gene expression of the unknown virus to produce suitable vaccination.
The assay kits mostly used are fluorescent protein-related assay kits, secreted alkaline phosphate(SEAP) assay kits, luciferase assay kits, beta-galactosidase assay kits, and others. This is attributed to their increased usage in expression studies and signaling pathway analysis during gene transcription or translation levels. Also, the extensive usage of assays enables precise signal measurement, maintaining the consistency of the outcomes. In addition, they are convenient, fast, sensitive, and display a broadly linear pattern for detection. Moreover, the rising focus of researchers on establishing high-throughput assays of beta-galactosidase for reporter systems based on bacterial cells contributes to the fastest growth rate of the assay kit segments. This huge surge in demand for the assay kits segment is expected to propel the 乐鱼体育官网's growth.
The launch of assay kits by 乐鱼体育官网 players is also propelling the growth of the segment. For instance, in June 2021, QIAGEN launched the QIAprep& amp; CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence.
Thus, owing to the abovementioned factors, the 乐鱼体育官网 segment is expected to propel the growth of the 乐鱼体育官网.
North America is Expected to Hold a Significant Share in the 乐鱼体育官网 and Expected to do Same in the Forecast Period.
The North American region is likely to dominate the global 乐鱼体育官网 owing to the technological innovations in the diagnostic and reporter gene assay products used for disease testing. The region will retain its dominant position over the forecast years on account of investments by biotechnology companies and health care facilities to accelerate the development of gene therapies.
The growing investment by biotechnological and pharmaceutical companies in establishing facilities dedicated to research and manufacturing of gene therapy and related genetic products also drives the growth of the 乐鱼体育官网. For instance, in December 2020, Taysha Gene Therapies, Inc. entered into a lease agreement to occupy and configure an approximately 187,000-square-foot commercial-scale current Good Manufacturing Practices (cGMP) manufacturing facility in Durham, North Carolina for preclinical, clinical, and commercial production of its gene therapy pipeline. Additionally, in December 2021, Pfizer Inc. reported the opening of a new, state-of-the-art clinical manufacturing facility in Durham, North Carolina. The facility expands Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer's continued investment in gene therapy research, development, and manufacturing.
In addition, the launch of products such as assay kits in the region is also propelling the growth of the 乐鱼体育官网. For instance, in November 2021, Asuragen, Inc., a Bio-Techne brand, launched a new kit to detect pathogenic variants in the CFTR gene, namely the AmplideX PCR/CE CFTR kit, intended for research use only. It provides broader coverage of the diverse United States population than any other commercially available, targeted CFTR testing assay. Such products, specifically targeting the United States population, are also propelling the growth of the 乐鱼体育官网.
Thus, owing to the abovementioned factors, the 乐鱼体育官网 in the North American region is expected to show growth over the forecast period.
Reporter Gene Assay Industry Overview
The Reporter Gene Assay 乐鱼体育官网 is competitive and consists of several major players. In terms of 乐鱼体育官网 share, a few of the major players are currently dominating the 乐鱼体育官网. Some companies currently dominating the 乐鱼体育官网 are Thermo Fisher Scientific, Puritan Medical Products, Trinity Biotech, Medical Wire & Equipment, Vircell, Quidel Corporation, BD, Titan Biotech Limited, Copan Diagnostics, EKF diagnostics, Hardy Diagnostics, Pretium Packaging, and others.
Reporter Gene Assay 乐鱼体育官网 Leaders
-
ThermoFisher Scientific
-
PerkinElmer, Inc
-
Merck KGaA
-
Bio-Rad Laboratories, Inc
-
Promega Corporation
- *Disclaimer: Major Players sorted in no particular order
Reporter Gene Assay 乐鱼体育官网 News
- In April 2022, at the World CDx Summit in London, Illumina entered into a long-term strategic collaboration with Janssen Biotech to accelerate the development of precision medicines. The collaboration aims to utilize Illumina's portfolio of resources, including AI-based genome interpretation tools, whole-genome sequencing, and multi-omic analysis services.
- In February 2022, Tesis Biosciences, one of the leaders in targeted genetic sequencing, acquired Genome Explorations to increase focus on clinical research and product development.
Reporter Gene Assay Industry Segmentation
As per the scope of this report, the reporter gene assists in recognizing a specific gene that has required expression or not in organisms. These reporter genes are also used as markers in the screening of transformed cells for research in gene expression and other processes. The Reporter Gene Assay 乐鱼体育官网 is by Product (Assay Kits and Reagents), Application (Gene Regulation, Cell signaling pathways, and Others), and Geography ( North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The 乐鱼体育官网 report also covers the estimated 乐鱼体育官网 sizes and trends of 17 countries across major regions globally. The report offers values in USD million for the above segments.
| By Product | Assay Kits | ||
| Reagents | |||
| By Application | Gene Regulation | ||
| Cell signalling pathways | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Assay Kits |
| Reagents |
| Gene Regulation |
| Cell signalling pathways |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Reporter Gene Assay 乐鱼体育官网 Research FAQs
What is the current Global Reporter Gene Assay 乐鱼体育官网 size?
The Global Reporter Gene Assay 乐鱼体育官网 is projected to register a CAGR of 10.1% during the forecast period (2025-2030)
Who are the key players in Global Reporter Gene Assay 乐鱼体育官网?
ThermoFisher Scientific, PerkinElmer, Inc, Merck KGaA, Bio-Rad Laboratories, Inc and Promega Corporation are the major companies operating in the Global Reporter Gene Assay 乐鱼体育官网.
Which is the fastest growing region in Global Reporter Gene Assay 乐鱼体育官网?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Reporter Gene Assay 乐鱼体育官网?
In 2025, the North America accounts for the largest 乐鱼体育官网 share in Global Reporter Gene Assay 乐鱼体育官网.
What years does this Global Reporter Gene Assay 乐鱼体育官网 cover?
The report covers the Global Reporter Gene Assay 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Reporter Gene Assay 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global Reporter Gene Assay Industry Report
Statistics for the 2025 Global Reporter Gene Assay 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Global Reporter Gene Assay analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
